Literature DB >> 16789881

A novel achiral seco-amino-cyclopropylindoline (CI) analog of CC-1065 and the duocarmycins: design, synthesis and biological studies.

James L Toth1, John D Trzupek, Lloyd V Flores, Konstantinos Kiakos, John A Hartley, William T Pennington, Moses Lee.   

Abstract

The design, synthesis and DNA binding properties of a novel achiral and amino-containing seco-cyclopropylindoline analog (seco-amino-CI-TMI, 1) of the duocarmycins are described. Thermal induced DNA cleavage studies on pUC18 DNA revealed compound 1 to preferentially bind in the minor groove and to covalently react with AT-rich sequences, particularly at the underlined adenine-N3 group of 5'-AAAAA(865)-3'. This sequence specificity is similar to adozelesin and CC-1065. Using a 4-day continuous exposure, compound 1 inhibited the growth of K562 human chronic myeloid leukemia cells in culture. Compound 1 has appreciable cytotoxicity (IC50 value of 1.30 microM) relative to compound 2 (0.15 microM), the corresponding racemic and hydroxy-seco-CI-TMI analog. These results indicate that the aminophenethyl chloride group present in compound 1 has similar sequence specific and cytotoxic properties to the hydroxy-containing seco-precursors of CC-1065 and the duocarmycins. Moreover, the results suggest that the chiral center present in the natural products is not absolutely necessary for biological activity. The novel aminophenethyl halide moiety is, therefore, a useful template from which to develop future achiral analogs of CC-1065 and the duocarmycins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16789881     DOI: 10.2174/1573406053402523

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  1 in total

1.  Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent.

Authors:  Elizabeth Rayburn; Wei Wang; Mao Li; Xu Zhang; Hongxia Xu; Haibo Li; Jiang-Jiang Qin; Lee Jia; Joseph Covey; Moses Lee; Ruiwen Zhang
Journal:  Cancer Chemother Pharmacol       Date:  2012-02-25       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.